Search
AZN.LN: Mystical Endpoints
What's the endpoint?: There have recently been some uncertainties surrounding the exact endpoint and timings of the upcoming MYSTIC combo study of Astra’s PD-L1 durvalumab with their CTLA4 tremelimumab in 1st line lung cancer. Specifically:What is MYSTIC’s primary endpoint? PFS, OS or both?How likely will MYSTIC meet its PFS endpoint?Will MYSTIC be delayed till 2018 to wait for an overall survival endpoint?
